Article Sidebar

Submitted
May 8, 2021
Published
May 8, 2021
Download
PDF
Statistic
Read Counter : 164 Download : 85

Main Article Content

Abstract

The main approach of the Nanocochleates is to target the cancer cells for the effective treatment against leukemia. Nanocochleate is more stable than any other drug carriers such as Liposomes, Niosomes, Nanoparticles and Nanoliposomes. Nanocochleate drug delivery is most effective in case of both hydrophilic and hydrophobic drugs. Cytarabine is used for the leukemic treatment since long time and its pharmacological effect is well established for the nanocochleate preparation, as it is suitable for the formulation: by increasing the half-life, to avoid getting converted to inactive metabolite by intestinal enzymes, increases the permeability, reduces the dose etc. The storage and release of the conventional dosage form was affected by environmental factors as it can be overcome by the nanocochleates. Nanocochleates are prepared by using the various cross-linking agent like, calcium chloride, zinc chloride and chitosan. The Nanocochleates is optimized by the Response surface methodology using a Box and Behnken’s design, as it allows the determination of various factors on nanocochleates properties with a minimum number of experiments. The drug loaded Nanocochleates was prepared with high entrapment efficiency and prolonged drug release. From the results it can be concluded that the novel Nanocochleates drug delivery system has a promising carrier for treatment of leukemia.

Keywords

Nanocochleates Cytarabine Cross-linkers Controlled drug delivery Target delivery

Article Details

How to Cite
Niranjana Vaidhya Anantharaman, Ubaidulla Udhumansha, & Grace Rathnam. (2021). Optimization of cytarabine loaded nanocochleates for targeting LEUKEMIA by response surface methodology . International Journal of Research in Pharmacology & Pharmacotherapeutics, 7(3), 205-221. https://doi.org/10.61096/ijrpp.v7.iss3.2018.205-221
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. [1]. Panwar V., Mahajan V., Panwar A. S., Darwhekar G. N, Jain D. K. Nanocochleate: As Drug Delivery Vehicle. International Journal of Pharmacy and Biological Sciences. 1(1), 2011, 31-38.
  2. [2]. A comprehensive cancer control program for BC, BC Cancer Agency Cancer Drug Manual© Cytarabine Developed:http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Cytarabine_monograph_May2014.pdf. 2014.
  3. [3]. Ramasamy, T., Khandasamy, U., Hinabindhu, R., Kona, K., Nanocochleate – A new drug delivery system. Fabad J. Pharm. Sci. 34, 2009, 91-101.
  4. [4]. Poudel I, Ahiwale R, Pawar A, Mahadik K, Bothiraja C. Development of novel biotinylated chitosan-decorated docetaxel-loaded nanocochleates for breast cancer targeting. Artif Cells Nanomed Biotechnol. 26, 2018, 1-12.
  5. [5]. Bothiraja C, Rajput N, Poudel I, Rajalakshmi S, Panda B, Pawar A. Development of novel biofunctionalized chitosan decorated nanocochleates as a cancer targeted drug delivery platform. Artif Cells Nanomed Biotechnol. 25, 2018, 1-15.
  6. [6]. Tamargo B, Monzote L, Piñón A, Machín L, García M, Scull R, Setzer WN. In Vitro and In Vivo Evaluation of Essential Oil from Artemisia absinthium L. Formulated in Nanocochleates against Cutaneous Leishmaniasis. Medicines (Basel). 9, 4(2), 2017.
  7. [7]. Liu M, Zhong X, Yang Z. Chitosan functionalized nanocochleates for enhanced oral absorption of cyclosporine A. Sci Rep. 23(7), 2017, 41322.
  8. [8]. Nagarsekar K, Ashtikar M, Steiniger F, Thamm J, Schacher FH, Fahr A. Micro-spherical cochleate composites: method development for monodispersed cochleate system. J Liposome Res; 27(1), 2017, 32-40.
  9. [9]. Jin, T., Zarif, L., & Mannino, R. Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents, U.S. Patent 6, 2000, 153, 217.
  10. [10]. Gould-Fogerite, S., & Mannino, R. J. Cochleate delivery vehicles, U.S. Patent 5, 1997, 994-318.
  11. [11]. Shivli Nomani, Jeyabalan Govinda Samy. Simultaneous loading of two antidiabetic agents in a nanoliposomal system: formulation development and characterization. Int J Adv Pharmacy Med Bio allied Sci. 3(3), 2015, 122-131.
  12. [12]. Zarif, L., & Perlin, D. Amphotericin B Nanocochleates: From Formulation to Oral Efficacy. Drug Delivery Technology, 2(4), 2002, 34-37.
  13. [13]. Delmarre, D., Lu, R., Tatton, N., Krause-Elsmore, S., Gould-Fogerite, S., & Mannino, R. J. Formulation of Hydrophobic Drugs Into Cochleate Delivery Vehicles: A Simplified Protocol & Formulation Kit. Drug Delivery Technology, 4(1), 2004, 64-69.
  14. [14]. Biodelivery sciences International Retrieved September 13, 2006 from http://www.biodeliverysciences.com/A boutNanocochleateTechnology.html 2005.
  15. [15]. O'Donnell, Francis E. JR., Gould-Fogerite, S., & Mannino, R. J., Apoprotein cochleate compositions U.S. Patent Application 2006/0019870 A1. 2006.
  16. [16]. Mannino, R. J., Gould-Fogerite, S., Krause-Elsmore, S. L., Delmarre, D., & Lu, R. Novel encochleation methods, cochleates and methods of use, U.S. Patent Application 2005/0013854 A1. 2005.
  17. [17]. Zarif, L., Jin, T., Segarra, I., Mannino, R. J. Hydrogel-isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules, U.S. Patent 6592894 2003.
  18. [18]. Sharma, S., Aggarwal, G., Novel technologies for oral delivery of poorly water-soluble drugs. Res Journal of Pharmaceutical, Biological and Chemical Sci. 1(4), 2010, 292-305.